H.C. Wainwright bullish on GeoVax Labs given ‘notable’ 1H23 achievements

H.C. Wainwright notes that earlier this month, GeoVax Labs (GOVX) reported Q2 financial results and operational updates highlighted by initiation of a new clinical trial with GEO-CM04S1. More specifically, in July 2023, GeoVax announced the start of an investigator-initiated and externally funded Phase 2 COVID-19 vaccine booster investigator-initiated clinical trial in patients with chronic lymphocytic leukemia, a recognized high-risk group.The firm is positive on the news, as the trial, which is designed to compare 04S1 vs. a bivalent mRNA vaccine marketed by Pfizer (PFE), is expected to enroll approximately 80 patients, and thus, with potential for rapid enrollment, could generate a high-value readout in early 2024. H.C. Wainwright reiterates a Buy rating on GeoVax with a price target of $8 as notable first half of 2023 achievements “set the stage for future success.”